Literature DB >> 8340923

Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.

J I DeGraw1, W T Colwell, J R Piper, F M Sirotnak.   

Abstract

Successive alkylation of dimethyl homoterephthalate with propargyl bromide and 2,4-diamino-6-(bromomethyl)pteridine followed by ester saponification at room temperature afforded 2,4-diamino-4-deoxy-10-carboxy-10-propargyl-10-deazapteroic acid. The 10-COOH was readily decarboxylated by heating in DMSO at a temperature of only 120 degrees C to yield the diamino-10-propargyl-10-deazapteroic acid intermediate. Coupling with diethyl L-glutamate and ester hydrolysis gave the title compound. The 10-propargyl analogue was about 5 times more potent than MTX as an inhibitor of growth in L1210 cells, but was only one-third as potent as an inhibitor of DHFR from L1210. The analogue was transported inward very effectively in L1210 cells showing a 10-fold advantage over MTX. At a dose of 36 mg/kg the 10-propargyl compound caused shrinkage of the E0771 solid murine mammary tumor to only 1% of untreated controls.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340923     DOI: 10.1021/jm00067a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

Review 1.  Targeted treatment and new agents in peripheral T-cell lymphoma.

Authors:  Jasmine M Zain; Owen O'Connor
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

Review 2.  Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.

Authors:  Catherine G Chung; Brian Poligone
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  The antifolates.

Authors:  Michele Visentin; Rongbao Zhao; I David Goldman
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

4.  Simultaneous Control of Endogenous and User-Defined Genetic Pathways Using Unique ecDHFR Pharmacological Chaperones.

Authors:  Prerana Ramadurgum; DaNae R Woodard; Steffi Daniel; Hui Peng; Prema L Mallipeddi; Hanspeter Niederstrasser; Melina Mihelakis; Viet Q Chau; Peter M Douglas; Bruce A Posner; John D Hulleman
Journal:  Cell Chem Biol       Date:  2020-04-23       Impact factor: 8.116

Review 5.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

6.  Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

Authors:  M Serova; I Bieche; M-P Sablin; G J Pronk; M Vidaud; E Cvitkovic; S Faivre; E Raymond
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

7.  Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.

Authors:  M Casanova; A Medina-Pérez; M Moreno-Beltran; M Mata-Vazquez; A Rueda
Journal:  Ther Clin Risk Manag       Date:  2011-10-07       Impact factor: 2.423

8.  Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

Authors:  Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld
Journal:  Cancer Manag Res       Date:  2012-03-12       Impact factor: 3.989

9.  Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma.

Authors:  Annabelle L Rodd; Katherine Ververis; Tom C Karagiannis
Journal:  Clin Med Insights Oncol       Date:  2012-08-21

Review 10.  Pralatrexate, a new hope for aggressive T-cell lymphomas?

Authors:  Antonio Rueda; María Casanova; Cristina Quero; Angeles Medina-Pérez
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.